HIGHLIGHTS
- who: MDPI from the Department of Surgery, Magellan Center, Bordeaux University Hospital, Pessac, France have published the article: Type of the Paper (Article, in the Journal: Cancers 2023, 15, 2188. of 19/02/2023
- what: The aim was combined evaluation of the tumor objective response (TOR) assessed computed tomography and the absence of major toxicities resulting in discontinuation of neoadjuvant chemotherapy (NCT) (45% and 90% respectively). This phase II study was carried out to evaluate the efficacy and toxicity of a regimen combining a targeted therapy, cetuximab, with an established 5-FU-cisplatin perioperative CT . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.